ASCO 2023 | INTRIGUE: ripretinib versus sunitinib in GIST

Robin Jones, MBBS, MRCP, MD, The Royal Marsden Hospital, London, UK, provides an overview of findings from the Phase III INTRIGUE trial (NCT03673501) of ripretinib in patients with gastrointestinal stromal tumor (GIST). Patients either received ripretinib or sunitinib, and progression-free survival was the primary endpoint. There was no statistically significant benefit for patients receiving ripretinib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.